Enterprise Financial Services Corp cut its holdings in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 52.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 10,632 shares of the biopharmaceutical company’s stock after selling 11,662 shares during the period. Enterprise Financial Services Corp’s holdings in Bristol-Myers Squibb were worth $678,000 at the end of the most recent reporting period.
Several other large investors have also bought and sold shares of the company. Vanguard Group Inc. grew its position in shares of Bristol-Myers Squibb by 0.3% during the 2nd quarter. Vanguard Group Inc. now owns 118,661,690 shares of the biopharmaceutical company’s stock valued at $6,611,829,000 after acquiring an additional 333,685 shares during the period. BlackRock Inc. grew its position in shares of Bristol-Myers Squibb by 2.4% during the 2nd quarter. BlackRock Inc. now owns 99,454,602 shares of the biopharmaceutical company’s stock valued at $5,541,612,000 after acquiring an additional 2,367,864 shares during the period. State Street Corp lifted its stake in shares of Bristol-Myers Squibb by 1.8% during the 1st quarter. State Street Corp now owns 68,893,779 shares of the biopharmaceutical company’s stock valued at $3,746,446,000 after buying an additional 1,223,457 shares in the last quarter. Dodge & Cox lifted its stake in shares of Bristol-Myers Squibb by 1.6% during the 2nd quarter. Dodge & Cox now owns 29,579,461 shares of the biopharmaceutical company’s stock valued at $1,648,168,000 after buying an additional 459,271 shares in the last quarter. Finally, Northern Trust Corp lifted its stake in shares of Bristol-Myers Squibb by 3.9% during the 2nd quarter. Northern Trust Corp now owns 24,041,862 shares of the biopharmaceutical company’s stock valued at $1,339,612,000 after buying an additional 910,496 shares in the last quarter. 69.67% of the stock is owned by institutional investors.
In other Bristol-Myers Squibb news, Director Theodore R. Samuels II purchased 4,000 shares of the stock in a transaction that occurred on Friday, December 15th. The stock was bought at an average cost of $62.30 per share, with a total value of $249,200.00. Following the transaction, the director now directly owns 22,000 shares in the company, valued at approximately $1,370,600. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Sandra Leung sold 156,582 shares of Bristol-Myers Squibb stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $63.37, for a total transaction of $9,922,601.34. Following the transaction, the executive vice president now directly owns 584,373 shares of the company’s stock, valued at $37,031,717.01. The disclosure for this sale can be found here. Company insiders own 0.23% of the company’s stock.
A number of brokerages recently commented on BMY. Citigroup set a $72.00 price target on shares of Bristol-Myers Squibb and gave the company a “buy” rating in a research note on Wednesday, October 25th. BMO Capital Markets set a $49.00 price target on shares of Bristol-Myers Squibb and gave the company a “sell” rating in a research note on Thursday, October 26th. Vetr cut shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $59.70 target price on the stock. in a research note on Friday, December 22nd. Zacks Investment Research cut shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a research note on Tuesday, January 9th. Finally, Jefferies Group cut shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $72.00 target price on the stock. in a research note on Monday, October 16th. Three investment analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $65.05.
Shares of Bristol-Myers Squibb Co (NYSE BMY) opened at $62.81 on Friday. The stock has a market cap of $102,800.00, a price-to-earnings ratio of 24.73, a price-to-earnings-growth ratio of 2.29 and a beta of 1.18. Bristol-Myers Squibb Co has a twelve month low of $46.01 and a twelve month high of $66.10. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.59 and a quick ratio of 1.46.
Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.77 by ($0.02). Bristol-Myers Squibb had a return on equity of 32.41% and a net margin of 20.56%. The firm had revenue of $5.25 billion during the quarter, compared to the consensus estimate of $5.20 billion. During the same period last year, the business earned $0.77 EPS. Bristol-Myers Squibb’s revenue was up 6.7% on a year-over-year basis. equities analysts expect that Bristol-Myers Squibb Co will post 2.99 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Thursday, February 1st. Stockholders of record on Friday, January 5th will be given a $0.40 dividend. This represents a $1.60 annualized dividend and a dividend yield of 2.55%. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. The ex-dividend date of this dividend is Thursday, January 4th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently 62.99%.
TRADEMARK VIOLATION NOTICE: This piece of content was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another website, it was illegally stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/01/14/enterprise-financial-services-corp-sells-11662-shares-of-bristol-myers-squibb-co-bmy.html.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.